Bi-weekly irinotecan hydrochloride and cisplatin as a second-line chemotherapy for patients with advanced gastric cancer.
To evaluate the effectiveness of bi-weekly administered irinotecan (CPT-11) and Cisplatin (CDDP) as a second-line chemotherapy for patients with advanced gastric cancer. We included 22 patients who were resistant to 5-fluorouracil (5-FU) -based chemotherapy. CPT-11 (80 mg/m (2)) and CDDP (25 mg/m(2)) were administered bi-weekly on days 1 and 15 of a 4-week-cycle, on an outpatient basis except for the first time. Outcome variables include tumor response, toxicity, and survival. Among all patients, 8 responded to the therapy, yielding an overall response rate of 36.4% (complete response, n=1; partial response, n=7), while 14 did not respond (stable disease, n=9; progressive disease, n=5). The time to progression was 5.3 months, and the median survival was 10.6 months. Adverse reactions included Grade 3 or 4 leucopenia (n=4; 18.2%), Grade 3 or 4 thrombocytopenia (n=1; 4.5%) but all of these patients recovered soon (within one week). Bi-weekly CPT-11 and CDDP treatment was effective and should be considered as a second-line chemotherapy for patients with advanced gastric cancer who are resistant to 5-FU based chemotherapy.